Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Mizuho Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $127.00
06:44am, Monday, 27'th Jul 2020
Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Mizuho from $105.00 to $127.00 in a report released on Thursday morning, The Fly reports. The brokerage currently has a neutral
Idorsia: A Unique Opportunity To Buy Discounted Shares
06:24pm, Tuesday, 21'st Jul 2020
A unique opportunity has developed for investors looking for a biotech to add to their portfolio. I will explain why the recent Cilag Holding decision has been misconstrued by some investors.
Charting a bull-flag breakout, S&P 500 extends rally as volatility recedes
04:24pm, Tuesday, 21'st Jul 2020
Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...
Three health-care stocks to watch as sector hits records
04:05pm, Tuesday, 21'st Jul 2020
Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.
Frontier Capital Management Co. LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
07:02am, Monday, 20'th Jul 2020
Frontier Capital Management Co. LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exch
Metrica Partners Sends Letter to Board of NBI Industrial Finance
03:01am, Monday, 20'th Jul 2020Metrica Partners Sends Letter to Board of NBI Industrial Finance
12:00am, Monday, 20'th Jul 2020
Metrica Partners Pte. Ltd. (“Metrica”) manages investment funds that are among the largest minority shareholders of NBI Industrial Finance Co. Ltd. (“
Neurocrine Biosciences, Inc. to Post Q2 2020 Earnings of $0.39 Per Share, William Blair Forecasts (NASDAQ:NBIX)
01:32am, Saturday, 18'th Jul 2020
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at William Blair increased their Q2 2020 earnings estimates for Neurocrine Biosciences in a note issued to investors on Thursd
National Bank of Canada : Investments announces changes to portfolio managers | MarketScreener
08:01pm, Friday, 17'th Jul 2020Building A 'No-Brainer' Portfolio Today: 3 Fundamental Elements
08:01pm, Wednesday, 15'th Jul 2020
You don't need to lock yourself into a particular kind of investing style (e.g., dividend). No one can stop you from holding both AMZN and AT&T at the same time.
'GILDing' the Lilly: COVID Progress in Spotlight Ahead of Health Sector Earnings
12:00am, Wednesday, 15'th Jul 2020
Stocks Analysis by JJ Kinahan covering: S&P 500, Eli Lilly and Company, Gilead Sciences Inc, Medtronic PLC. Read JJ Kinahan's latest article on Investing.com
Charting a bull-trend whipsaw, S&P 500 nails next resistance
04:35pm, Tuesday, 14'th Jul 2020
Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...
Did Hedge Funds Make The Right Call On Neurocrine Biosciences, Inc. (NBIX)?
11:16pm, Monday, 13'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
08:01pm, Monday, 13'th Jul 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020. Neurocrine will then host a c
